Cutia Therapeutics (HKG:2487) said its topical 4% minocycline foam obtained marketing approval from China's National Medical Products Administration, according to a Tuesday filing with the Hong Kong bourse.
The topical treatment is used to treat patients as young as nine and adults with non-nodular moderate to severe acne vulgaris, the filing added.